Imatinib has been the first-line option for chronic myeloid leukemia (CML) and provides excellent outcomes for many. However, a number of patients were resistant to or intolerant of imatinib. This study aims to evaluate the 2-year results of treatment with nilotinib in these resistant or intolerant patients. | Efficacy of nilotinib in chronic myeloid leukemia patients resistant to or intolerant of imatinib: Results after 2 years